Table 2 Tumor characteristics in a Swedish cohort of 934 patients diagnosed with breast cancer between 2002-2011
From: Pre- and postoperative alcohol consumption in breast cancer patients: impact on early events
Preoperative alcohol consumption during the last week | |||||
|---|---|---|---|---|---|
Non-consumers | Moderate | High | |||
Patients included in the survival analyses | 0 drinks/week | 1-3 drinks/week | 4-9 drinks/week | 10+ drinks/week | |
n = 934 | 300 (32.1%) | 369 (39.5%) | 232 (24.8%) | 33 (3.5%) | |
Neoadjuvant therapy | 0 | 0 | 0 | 0 | 0 |
Preoperative interstitial laser thermotherapy | 0 | 0 | 0 | 0 | 0 |
Missing | 0 | 0 | 0 | 0 | 0 |
No preoperative treatment | 934 | 272 | 343 | 217 | 32 |
Pathological tumor size | |||||
In Situ | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
1 (≤20 mm) | 679 (72.47) | 215 (71.7%) | 271 (73.4%) | 169 (72.8%) | 24 (72.7%) |
2 (21-50 mm) | 238 (25.5%) | 77 (25.7%) | 92 (24.9%) | 60 (25.9%) | 9 (27.3%) |
3 (≥51 mm) | 15 (1.6%) | 8 (2.7%) | 5 (1.4%) | 2 (0.9%) | 0 (0.0%) |
4 (skin or muscular involvement independent of size) | 2 (0.2%) | 0 (0.0%) | 1 (0.3%) | 1 (0.4%) | 0 (0.0%) |
Invasive tumor size ≥21 mm or skin or muscular involvement | 255 (27.3%) | 85 (28.3%) | 98 (26.6%) | 63 (27.2%) | 9 (27.3%) |
Missing | 0 | 0 | 0 | 0 | 0 |
Axillary node involvement | |||||
0 | 572 (61.4%) | 188 (63.1%) | 227 (61.5%) | 134 (57.8%) | 23 (69.7%) |
1-3 | 277 (29.5%) | 80 (26.8%) | 111 30.1%) | 78 (33.6%) | 8 (24.2%) |
4+ | 83 (8.9%) | 30 (10.1%) | 31 (8.4%) | 20 (8.6%) | 2 (6.1%) |
Any axillary lymph node | 360 (38.6%) | 110 (36.9%) | 142 (38.5%) | 98 (42.2%) | 10 (30.3%) |
Missing | 2 | 2 | 0 | 0 | 0 |
Histological grade | |||||
I | 229 (24.5%) | 64 (21.4%) | 103 (27.9%) | 54 (23.3%) | 8 (24.2%) |
II | 472 (50.6%) | 158 (52.8%) | 175 (47.4%) | 118 (50.9%) | 21 (63.6%) |
III | 232 (24.9%) | 77 (25.8%) | 91 (24.7%) | 60 (25.9%) | 4 (12.1%) |
Missing | 1 | 1 | 0 | 0 | 0 |
Hormone receptor status | |||||
ER+ | 813 (87.2%) | 249 (83.0%) | 334 (90.8%) | 202 (87.4%) | 28 (84.8%) |
PgR+ | 656 (70.4%) | 205 (68.3%) | 260 (70.7%) | 168 (72.7%) | 23 (69.7%) |
ER + PgR+ | 650 (69.7%) | 202 (67.3%) | 259 (70.4%) | 166 (71.9%) | 23 (69.7%) |
ER + PgR- | 163 (17.5%) | 47 (15.7%) | 75 (20.4%) | 36 (15.6%) | 5 (15.2%) |
ER-PgR- | 113 (12.1%) | 48 (16.0%) | 33 (9.0%) | 27 (11.7%) | 5 (15.2%) |
ER-PgR+ | 6 (0.6%) | 3 (1.0%) | 1 (0.3%) | 2 (0.9%) | 0 (0.0%) |
Missing | 2 | 0 | 1 | 1 | 0 |